What Is Tamoxifen? Dosage, Half-Life & How to Track It

What tamoxifen is and how it works

Tamoxifen is a selective estrogen receptor modulator: an estrogen-receptor antagonist in breast tissue, but a partial agonist elsewhere in the body (bone, uterus) — the “selective” part of the name. In breast tissue specifically, blocking the receptor directly is why tamoxifen treats gynecomastia even without lowering circulating estradiol the way an aromatase inhibitor does.

In men, tamoxifen also blocks estrogen receptors at the hypothalamus, removing estrogen’s negative-feedback signal and driving up GnRH, LH, and FSH — and with them, endogenous testosterone production. That’s the same broad mechanism clomiphene (a related SERM) uses. The two off-label roles follow from those two separate actions: direct breast-tissue receptor blockade for acute gynecomastia, and HPTA stimulation for post-cycle “PCT” protocols meant to restart natural testosterone production after exogenous AAS use.

One added wrinkle: tamoxifen needs CYP2D6 metabolism to form its more potent active metabolites (4-hydroxytamoxifen and endoxifen). People who are genetically “poor metabolizers” at that enzyme get less of the active form from the same dose — a real, documented source of variable response between individuals.

Dosing & the taper approach

The FDA dose for breast cancer is 20 mg once daily, continuous. Off-label PCT protocols commonly follow a taper instead of a flat dose — a widely referenced pattern runs roughly 40 mg for the first one to two weeks, then 20 mg for two more, front-loading a higher dose to reach useful blood levels faster than the slow natural buildup described below would otherwise allow. There’s no single official version of this protocol; it varies with what preceded it and how suppressed the HPTA is.

For gynecomastia treatment, doses in the same 10–20 mg range are used for a defined period rather than as a taper.

The classic taper (e.g. 40/40/20/20 mg over four weeks) is a community convention, not an FDA-labeled schedule — it’s built around loading tamoxifen faster than its slow natural buildup would otherwise allow.

Half-life & why effects can lag

Tamoxifen’s own half-life is around 5–7 days, but its more potent active metabolites — formed via CYP2D6 — accumulate more slowly. The FDA label describes tamoxifen itself reaching steady state after about 4 weeks of daily dosing, with its main metabolite reaching steady state even later. That slow ramp is exactly why taper protocols front-load a higher dose: to get useful blood levels faster instead of waiting a month for a flat 20 mg/day to build up on its own.

It also means effects — and side effects — can persist for weeks after stopping, since the metabolites clear on their own slow timeline. Worth knowing before assuming a stopped protocol is fully “out of your system” the following week.

What to track — and the clot-risk warning

For PCT use, track LH, FSH, total/free testosterone, and estradiol — the same labs as clomiphene, since the HPTA-restart mechanism is comparable. For gynecomastia treatment, tracking the physical change (tenderness, tissue size) over weeks is the practical marker.

Tamoxifen’s FDA label carries a boxed warning for increased risk of blood clots (deep vein thrombosis, pulmonary embolism) and stroke — drawn mainly from long-term use data in women, but the underlying vascular mechanism isn’t sex-specific. Sudden leg swelling or pain, chest pain, or shortness of breath are symptoms worth taking seriously regardless of why someone is taking it. Visual disturbances are also a documented, rarer effect, similar to clomiphene.

Frequently asked questions